Abstract:Summary Heavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago, are exclusively found in camelids, comprising dromedaries, camels, llamas, and vicugnas. Nanobodies have become an essential tool in biomedical research and medicine, both in diagnostics and therapeutics due to their beneficial properties: small size, high stability, strong antigen‐binding affinity, low immunogenicity, low production cost, and straightforward engineering into more potent affinity reagents. The occurrence of HCAbs in camelids remains intriguing. It is believed to be an evolutionary adaptation, equipping camelids with a robust adaptive immune defense suitable to respond to the pressure from a pathogenic invasion necessitating a more profound antigen recognition and neutralization. This evolutionary innovation led to a simplified HCAb structure, possibly supported by genetic mutations and drift, allowing adaptive mutation and diversification in the heavy chain variable gene and constant gene regions. Beyond understanding their origins, the application of nanobodies has significantly advanced over the past 30 years. Alongside expanding laboratory research, there has been a rapid increase in patent application for nanobodies. The introduction of commercial nanobody drugs such as Cablivi, Nanozora, Envafolimab, and Carvykti has boosted confidence among in their potential. This review explores the evolutionary history of HCAbs, their ontogeny, and applications in biotechnology and pharmaceuticals, focusing on approved and ongoing medical research pipelines.

Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.

Single domain antibody: Development and application in biotechnology and biopharma

Nanobodies: natural single-domain antibodies.

Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies

Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications

Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies

Nanobodies: From High-Throughput Identification to Therapeutic Development

Application Progress of the Single Domain Antibody in Medicine

Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook

Heterologous Expression of Nanobodies: a Recent Progress

The Small and Powerful Nanobodies (nbs) Originating from Peculiar Animals Used for Therapy of Cancers

Nanobody-based heavy chain antibodies and chimeric antibodies

Nanobodies: a promising approach to treatment of viral diseases

[Application of nanobody in cancer treatment].

Nanobody Technology: A Versatile Toolkit for Microscopic Imaging, Protein–Protein Interaction Analysis, and Protein Function Exploration

Current Status of Nanobody Technology: Applications in Disease Diagnosis and Therapy

Research Progress of Nanobodies in Diagnosis and Therapy of Tumor

NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions

Single domain antibodies from camelids in the treatment of microbial infections

Recent advances of nanobody applications in diagnosis and detection

A new generation of nanobody research tools using improved mass spectrometry-based discovery methods